Article

Responders to renal cell carcinoma agent show longer survival rates

Responders to the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) have significantly longer progression-free survival and overall survival than non-responders, according to an analysis of 1,059 patients who participated in six clinical trials of sunitinib as first- or second-line therapy of metastatic renal cell carcinoma.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
Related Content
Blurred interior of hospital - abstract medical background. | Image Credit: © jakkapan - stock.adobe.com
May 15th 2025

Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy

Professor Andreas Skolarikos Hannah Clarke
Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Published data support safety, efficacy of vaginal insert for SUI
May 14th 2025

Published data support safety, efficacy of vaginal insert for SUI

Hannah Clarke
Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
Long-term data point to durable efficacy of Optilume for urethral strictures
May 13th 2025

Long-term data point to durable efficacy of Optilume for urethral strictures

Hannah Clarke
The freedom from re-intervention rate was 71%.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke
Use of focal therapy was shown to prolong the duration of active surveillance.
© 2025 MJH Life Sciences

All rights reserved.